Cycclone Inc. (CYCL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | - | 0 | - | 0 | - |
| Operating profit | $m | -0 | -0 | ||||||
| Net profit | $m | - | - | -1 | - | 1 | - | 1 | - |
| EPS reported | $ | 0.00 | 0.02 | ||||||
| Operating cashflow per share | $ | -0.00 | -0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -0.00 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -0 | 0 | ||||||
| Book value equity | $m | 0 | - | ||||||
| Book value per share | $ | 0.00 | -0.00 | ||||||
| Number of shares | m | 840.04 | 40.98 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 55.56 | 1.94 | ||||||
| P/B LTM | x | 32.80 | -899.03 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -21.14 | -54.68 | ||||||
| EV/EBITDA LTM | x | -20.95 | -29.98 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | +1.80% | +51.55% | ||||||
| FCF Yield | % | -4.73% | -1.83% | ||||||
| Quality | |||||||||
| ROE | % | +1259.25% | +2566.85% | ||||||
| ROIC | % | -1.98% | -2.15% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +2177.78% | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | +4.21% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | -0.85 | ||||||
| Net Debt/EBITDA | x | 0.01 | -0.64 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +2.69% | ||||||
| Net debt/Equity | x | -0.01 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cycclone Inc., operating with its subsidiaries, specializes in the development, promotion, and distribution of bacteria-derived products. These offerings primarily function as beneficial additives for both agricultural crops and animal feed within the People's Republic of China. The company's product line includes various biological bacterium blends, notably those based on Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM). For crop cultivation, these AM/HM blends – exemplified by Bulgaria lactobacillus, beer microzyme, and dark red spirilla – are designed to boost beneficial microbial populations in soil, suppress harmful fungi and putrefactive bacteria, enhance nutrient absorption, and ultimately help mitigate diseases in crops and livestock. In the livestock sector, AM/HM-based feed additives serve to tenderize feed, inhibit the growth of pathogenic bacteria, and provide crucial nutrients such as organic acids, vitamins, enzymes, antibiotics, mycelium protein, and other growth stimulants, thereby ensuring a balanced nutritional intake. Furthermore, Cycclone offers FGW bacterial preservatives, utilized for preserving animal specimens in scientific research and extending the freshness of agricultural produce. It also supplies bacteria-based fertilizers for foliar application on fruits and vegetables. Beyond its biotechnology operations, the company holds investments in residential and commercial real estate. Founded in 2004 as China Dasheng Biotechnology Co., the company officially adopted the name Cycclone Inc. in May 2025 and is headquartered in Lanzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cycclone Inc., operating with its subsidiaries, specializes in the development, promotion, and distribution of bacteria-derived products. These offerings primarily function as beneficial additives for both agricultural crops and animal feed within the People's Republic of China. The company's product line includes various biological bacterium blends, notably those based on Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM). For crop cultivation, these AM/HM blends – exemplified by Bulgaria lactobacillus, beer microzyme, and dark red spirilla – are designed to boost beneficial microbial populations in soil, suppress harmful fungi and putrefactive bacteria, enhance nutrient absorption, and ultimately help mitigate diseases in crops and livestock. In the livestock sector, AM/HM-based feed additives serve to tenderize feed, inhibit the growth of pathogenic bacteria, and provide crucial nutrients such as organic acids, vitamins, enzymes, antibiotics, mycelium protein, and other growth stimulants, thereby ensuring a balanced nutritional intake. Furthermore, Cycclone offers FGW bacterial preservatives, utilized for preserving animal specimens in scientific research and extending the freshness of agricultural produce. It also supplies bacteria-based fertilizers for foliar application on fruits and vegetables. Beyond its biotechnology operations, the company holds investments in residential and commercial real estate. Founded in 2004 as China Dasheng Biotechnology Co., the company officially adopted the name Cycclone Inc. in May 2025 and is headquartered in Lanzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free